We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cyclacel Pharmaceuticals Inc (CYCC) USD0.001

Sell:$1.02 Buy:$1.12 Change: $0.012 (1.15%)
Market closed |  Prices as at close on 30 August 2024 | Switch to live prices |
Sell:$1.02
Buy:$1.12
Change: $0.012 (1.15%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 30 August 2024 | Switch to live prices |
Sell:$1.02
Buy:$1.12
Change: $0.012 (1.15%)
Market closed |  Prices as at close on 30 August 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.

Contact details

Address:
200 Connell Dr Ste 1500
BERKELEY HEIGHTS
07922-2811
United States
Telephone:
+1 (908) 5177330
Website:
https://cyclacel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CYCC
ISIN:
US23254L8019
Market cap:
$2.19 million
Shares in issue:
1.97 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Spiro Rombotis
    President, Chief Executive Officer, Director
  • Paul Mcbarron
    Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director
  • Brian Schwartz
    Interim Chief Medical Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.